Abstract：Objective To study the expression of microRNA-495-5p (miRNA-495-5p) in the serum of preterm infants with bronchopulmonary dysplasia (BPD) based on a bioinformatics analysis, and to provide a theoretical basis for further research on the association between miRNA-495-5p and BPD. Methods A total of 40 preterm infants who were admitted to the neonatal intensive care unit from January 2015 to December 2016 were enrolled. Among these infants, 20 with early clinical manifestations of BPD were enrolled as the BPD group, and 20 without such manifestations were enrolled as the control group. Peripheral blood samples were collected. The miRNA microarray technique was used to screen out differentially expressed miRNAs in serum between the two groups. RT-PCR was used for validation of results. TargetScan, miRDB, and miRWalk databases were used to predict the target genes of miRNA-495-5p. The DAVID database was used to perform gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of the target genes. Results Compared with the control group, the BPD group had a significant increase in the expression of miRNA-495-5p in serum (P < 0.05). A total of 117 target genes of miRNA-495-5p were predicted by the above three databases and they were involved in several molecular functions (including transcriptional regulatory activity, transcriptional activation activity, and transcription cofactor activity), biological processes (such as metabolic regulation, DNA-dependent transcriptional regulation, and vascular pattern), and cell components (including nucleoplasm, membrane components, and insoluble components) (P < 0.05). As for signaling pathways, these genes were significantly enriched in the mTOR signaling pathway (P < 0.05). Conclusions MiRNA-495-5p may be involved in the development and progression of BPD by regulating angiogenesis, stem cell differentiation, apoptosis, and autophagy, which provides clues for further research on the role and functional mechanism of miRNA-495-5p in BPD.
SUN Yi-Fan,MA Li,GONG Xiao-Hui et al. Expression of microRNA-495-5p in preterm infants with bronchopulmonary dysplasia: a bioinformatics analysis[J]. CJCP, 2020, 22(1): 24-30.
Kalikkot Thekkeveedu R, Guaman MC, Shivanna B. Bronchopulmonary dysplasia:a review of pathogenesis and pathophysiology[J]. Respir Med, 2017, 132:170-177.
[2]
Bancalari E, Jain D. Bronchopulmonary dysplasia:50 years after the original description[J]. Neonatology, 2019, 115(4):384-391.
[3]
Ballard PL. Hormonal regulation of pulmonary surfactant[J]. Endocr Rev, 1989, 10(2):165-181.
[4]
Gross I. Regulation of fetal lung maturation[J]. Am J Physiol, 1990, 259(6 Pt 1):L337-L344.
[5]
Herriges M, Morrisey EE. Lung development:orchestrating the generation and regeneration of a complex organ[J]. Development, 2014, 141(3):502-513.
[6]
Bhaskaran M, Wang Y, Zhang H, et al. MicroRNA-127 modulates fetal lung development[J]. Physiol Genomics, 2009, 37(3):268-278.
[7]
Sun YF, Kan Q, Yang Y, et al. Knockout of microRNA26a promotes lung development and pulmonary surfactant synthesis[J]. Mol Med Rep, 2018, 17(4):5988-5995.
[8]
Nana-Sinkam SP, Karsies T, Riscili B, et al. Lung microRNA:from development to disease[J]. Expert Rev Respir Med, 2009, 3(4):373-385.
[9]
Zhao X, Wang T, Cai B, et al. MicroRNA-495 enhances chondrocyte apoptosis, senescence and promotes the progression of osteoarthritis by targeting AKT1[J]. Am J Transl Res, 2019, 11(4):2232-2244.
[10]
Yang Y, Pu XD, Qing K, et al. Identification of differentially expressed microRNAs and the possible role of miRNA-126* in Sprague-Dawley rats during fetal lung development[J]. Mol Med Rep, 2013, 7(1):65-72.
Bartel DP. MicroRNAs:genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2):281-297.
[13]
Ahmadi A, Khansarinejad B, Hosseinkhani S, et al. miR-199a-5p and miR-495 target GRP78 within UPR pathway of lung cancer[J]. Gene, 2017, 620:15-22.
[14]
Welten SM, Bastiaansen AJ, de Jong RC, et al. Inhibition of 14q32 microRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia[J]. Circ Res, 2014, 115(8):696-708.
[15]
Collison A, Herbert C, Siegle JS, et al. Altered expression of microRNA in the airway wall in chronic asthma:miR-126 as a potential therapeutic target[J]. BMC Pulm Med, 2011, 11:29.
[16]
Sun C, Zhang S, Wang J, et al. EPO enhances the protective effects of MSCs in experimental hyperoxia-induced neonatal mice by promoting angiogenesis[J]. Aging (Albany NY), 2019, 11(8):2477-2487.
[17]
Leeman KT, Pessina P, Lee JH, et al. Mesenchymal stem cells increase alveolar differentiation in lung progenitor organoid cultures[J]. Sci Rep, 2019, 9(1):6479.
[18]
Mei Y, Chen C, Dong H, et al. Treatment of hyperoxia-induced lung injury with lung mesenchymal stem cells in mice[J]. Stem Cells Int, 2018, 2018:5976519.
Liu Y, Pejchinovski M, Wang X, et al. Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease[J]. Sci Rep, 2018, 8(1):5584.
[21]
Wang J, Feng W, Dong Y, et al. MicroRNA-495 regulates human gastric cancer cell apoptosis and migration through Akt and mTOR signaling[J]. Oncol Rep, 2018, 40(6):3654-3662.
[22]
Sureshbabu A, Syed M, Das P, et al. Inhibition of regulatory-associated protein of mechanistic target of rapamycin prevents hyperoxia-induced lung injury by enhancing autophagy and reducing apoptosis in neonatal mice[J]. Am J Respir Cell Mol Biol, 2016, 55(5):722-735.
